InflaRx
Manufacturing · Germany · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Winzerlaer St 2, Jena, Thuringia, 07745,...Phone Number
+49 493641508180Website
www.inflarx.deRevenue
<$5 MillionStock Symbol
IFRXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About InflaRx
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary technology to discover and develop first-in-class or best-in-class, potent and specific inhibitors of C5a and C5aR. Complement C5a and C5aR are powerful inflammatory mediators involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA.Explore more
InflaRx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is InflaRx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at InflaRx
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when InflaRx launches new products
Click to see if InflaRx had a recent Job posting/layoffs
Funding: Get notified immidiatlly once InflaRx has new funding data
Earning: See what the market has to say on InflaRx recently announced quarterly report
Check out if InflaRx is spiking on competitors!
Check if InflaRx has recently received funding, and reach out quickly before it becomes old news!
InflaRx, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at InflaRx
Find 3 more new buyers
Company Profile Activity
Activity Insights
InflaRx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
InflaRx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about InflaRx.
InflaRx Tech Stack
A closer look at the technologies used by InflaRx
Most Recent Scoops
Project
InflaRx has reported that its partner in China has reproduced the same Phase 2 data with the out-licensed antibody and received permission from the Chinese FDA to start a Phase 3 trial, which is already enrolling patients.
Pharmaceuticals, Clinical Operations
Pain Point
InflaRx has identified that avacopan did not receive FDA label approval for corticosteroid sparing because the drug blocks the CYP3A4/5 enzyme in the liver, which also metabolizes corticosteroids. The FDA stated that while lower intake was shown, lower blood levels were not proven, and the drug has experienced liver toxicity signals related to this enzyme inhibition.
Compliance, Pharmaceuticals, Regulations
Project
InflaRx is seeking to attract strategic partners to collaborate on alternative indications for izicopan beyond hidradenitis suppurativa. The company believes the small oral molecule has significant pipeline potential that is difficult for a small company to fully exploit alone.
Business Development
Project
InflaRx has announced a key focus on izicopan development, with the entire team concentrating on next steps in hidradenitis suppurativa (HS) development. The company will host a capital markets update in spring to discuss the regulatory path.
Product Development, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
InflaRx News & Media
Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now
InflaRx N.V. (NASDAQ:IFRX) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 13, 2026, Raymond James upgraded InflaRx N.V. (NASDAQ:IFRX) to Strong Buy from Outperform with a price target of $9, up from $7. Raymond James said sentiment is increasingly supported by a constructive view of InflaRx’s izicopan program in […]InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases May 8, 2026 8:30 AM EDTCompany ParticipantsJan...InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. The aggregate gross proceeds from the offering were $150 million, before deducting the underwriting discount and offering expenses.InflaRx N.V. (IFRX) Regains Compliance With Nasdaq
InflaRx N.V. (NASDAQ:IFRX) is one of the top 10 hot penny stocks to buy now. InflaRx N.V. (NASDAQ:IFRX) announced on April 28 that it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on April 27, informing management that the company regained compliance with Nasdaq’s minimum bid price requirement […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding InflaRx
Sign Up For FreeTo access detailed company insights
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary technology to discover and develop first-in-class or best-in-class, potent and specific inhibitors of C5a and C5aR. Complement C5a and C5aR are powerful inflammatory mediators involved in the progression of a wide variety of autoimmune and other... Read More
